-
Goldman Removes Mylan From Its Conviction List
Friday, May 13, 2016 - 9:17am | 303Read More...Mylan NV (NASDAQ: MYL) shares have declined 28 percent since mid-December 2015, as compared to the 1 percent appreciation in the S&P 500. Goldman Sachs’ Jami Rubin maintains a Buy rating and price target of $60 on the company, while removing it from the "Americas Conviction List." Generic...
-
Allergan Is Primed For Growth, Goldman Sees 27% Upside Potential
Friday, May 13, 2016 - 8:00am | 344Read More...The 1Q earnings call hosted by Allergan plc Ordinary Shares (NYSE: AGN) gave a lot of confidence in the company’s underlying business, Goldman Sachs’ Jami Rubin said in a report. The analyst maintained a Buy rating for Allergan, with a price target of $275. He added the stock to the...
-
Goldman Downgrades Zoetis, Sees Limited Upside
Friday, May 6, 2016 - 12:07pm | 176Read More...Goldman Sachs’ Jami Rubin believes that while Zoetis Inc (NYSE: ZTS)'s stock is fairly valued at present, it has limited upside potential of about 2 percent. Rubin downgraded the rating on the company from Neutral to Sell, while raising the price target from $46 to $48. Stock...
-
Bristol-Myers Squibb Target, Estimates Under Review At Goldman Sachs
Thursday, April 28, 2016 - 1:05pm | 294Read More...Bristol-Myers Squibb Co (NYSE: BMY) reported strong 1Q results, while raising its guidance for 2016. 1Q Beat Goldman Sachs’ Jami Rubin mentioned that the company adjusted EPS for 1Q came in at $0.74, beating both the estimate and the consensus. Revenues at $4.39 billion also significantly...
-
Goldman Selling Perrigo, Prefers Mylan And Teva
Tuesday, April 26, 2016 - 7:38am | 315Read More...Perrigo Company plc Ordinary Shares (NYSE: PRGO) shares plunged after the company announced a change in CEO and reduced its EPS guidance for 1Q and FY16, citing Rx pricing pressure, lower expectations from Omega and fewer new product launches. Goldman Sachs’ Jami Rubin reiterated a Sell...
-
Goldman Reinstates Coverage On Pfizer And Allergan Following Failed Merger
Monday, April 18, 2016 - 8:06am | 342Read More...The collapse of the $160bn merger between Pfizer Inc. (NYSE: PFE) and Allergan plc Ordinary Shares (NYSE: AGN) added to the burgeoning total value of deals abandoned in 2016. Goldman Sachs’ Jami Rubin reinitiated coverage of both the stocks in separate reports. Pfizer Analyst Jami Rubin...
-
Goldman Upgrades Johnson & Johnson, Removes From America's Sell List
Monday, March 14, 2016 - 8:13am | 342Read More...Goldman Sachs’ Jami Rubin upgraded the rating for Johnson & Johnson (NYSE: JNJ), from Sell to Neutral on improving optionality. The price target has been raised from $102 to $112. A conglomerate structure has led to Johnson & Johnson having “significant trapped value....
-
Johnson & Johnson Sales Fall: What The Street Is Saying Now
Tuesday, October 13, 2015 - 12:25pm | 431Read More...Johnson & Johnson (NYSE: JNJ)’s Q3 revenue came up short of consensus estimates, but the company managed a beat on its EPS number. The company also announced an additional $10 billion in share buybacks. Wall Street firms and the market seem split on how to interpret the company’s...
-
UPDATE: Goldman Sachs Upgrades Teva Pharmaceutical Industries
Wednesday, March 19, 2014 - 2:17pm | 122Read More...Goldman Sachs on Wednesday upgraded shares of Teva Pharmaceutical Industries (NYSE: TEVA) from Sell to Neutral and raised the price target from $40 to $52. Analyst Jami Rubin expects the “narrative around TEVA to change from concerns around a declining Copaxone franchise to growth and optionality...
-
UPDATE: Goldman Sachs Downgrades Eli Lilly & Company on Relative Lack of Differentiation in Pipeline
Monday, November 11, 2013 - 11:17am | 153Read More...In a report published Monday, Goldman Sachs analyst Jami Rubin downgraded the rating on Eli Lilly & Company (NYSE: LLY) from Neutral to Sell, and lowered the price target from $52.00 to $48.00. In the report, Goldman Sachs noted, “As LLY's primary care business declines due to patent...
-
UPDATE: Goldman Sachs Upgrades Johnson & Johnson Based on Solid Pharma Business
Friday, October 11, 2013 - 10:24am | 186Read More...In a report published Friday, Goldman Sachs analyst Jami Rubin upgraded Johnson & Johnson (NYSE: JNJ) from Sell to Neutral and raised the 12 month PT from $87 to $95. Rubin noted Johnson and Johnson's solid pharma business performance this year, commenting on launches of Xarelto, Invokana, and...
-
UPDATE: Goldman Sachs Raises PT on Mylan on Increased Confidence in Key Revenue/Earnings Drivers
Thursday, September 12, 2013 - 10:51am | 173Read More...In a report published Thursday, Goldman Sachs analyst Jami Rubin reiterated a Buy rating on Mylan (NASDAQ: MYL), and raised the price target from $40.00 to $46.00. In the report, Goldman Sachs noted, “We raise our estimates on increased confidence in key revenue and earnings drivers. Our new...
-
UPDATE: Goldman Sachs Upgrades Perrigo on Multiple Positive Factors
Tuesday, July 30, 2013 - 8:43am | 169Read More...In a report published Tuesday, Goldman Sachs analyst Jami Rubin upgraded Perrigo (NYSE: PRGO) from Sell to Neutral, and raised the price target from $122.00 to $132.00. In the report, Goldman Sachs noted, “We upgrade PRGO to Neutral from Sell. We are more favorable on the company's future...
-
UPDATE: Goldman Sachs Downgrades Teva Pharmaceuticals on Brand Focus Taking Time
Tuesday, July 30, 2013 - 7:51am | 139Read More...In a report published on Monday, Goldman Sachs analyst Jami Rubin downgraded Teva Pharmaceuticals (NYSE: TEVA) from Neutral to Sell and lowered the price target on the company from $41 to $40. In the report, Goldman Sachs stated, "While the pharma space has been awash with accretive deal...
-
UPDATE: Goldman Sachs Upgrades Forest Laboratories on Increased Potential for Strategic Options
Friday, June 21, 2013 - 8:56am | 165Read More...In a report published on Friday, Goldman Sachs analyst Jami Rubin upgraded the rating on Forest Laboratories (NYSE: FRX) from Neutral to Buy and raised the price target from $40 to $50. In the report, Goldman Sachs noted, "We upgrade FRX to Buy from Neutral on increased potential opportunities...
